IE910820A1
(en)
*
|
1990-03-22 |
1991-09-25 |
Sloan Kettering Inst Cancer |
Gp75 as a tumor vaccine for melanoma
|
WO1993002556A1
(en)
*
|
1991-07-26 |
1993-02-18 |
University Of Rochester |
Cancer therapy utilizing malignant cells
|
US5462871A
(en)
*
|
1992-08-31 |
1995-10-31 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules which encode MAGE derived nonapeptides
|
EP0721345B1
(de)
*
|
1993-08-11 |
2005-08-31 |
Jenner Technologies |
Impfstoff gegen prostatakrebs
|
ES2224113T5
(es)
*
|
1994-02-16 |
2009-05-01 |
The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Polipeptido antigenico asociado al melanoma, epitopos del mismo y vacunas contra melanoma.
|
CA2188432C
(en)
|
1994-04-22 |
2011-02-01 |
Yutaka Kawakami |
Melanoma antigens
|
US5874560A
(en)
*
|
1994-04-22 |
1999-02-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Melanoma antigens and their use in diagnostic and therapeutic methods
|
US8791237B2
(en)
*
|
1994-11-08 |
2014-07-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of non-hodgkins lymphoma
|
US20070264279A1
(en)
*
|
1994-11-08 |
2007-11-15 |
Claudia Gravekamp |
Compositions and methods comprising a MAGE-b antigen
|
US7662396B2
(en)
*
|
2001-03-26 |
2010-02-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for enhancing the immunogenicity of antigens
|
US8956621B2
(en)
|
1994-11-08 |
2015-02-17 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of cervical dysplasia
|
US7794729B2
(en)
*
|
1994-11-08 |
2010-09-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for immunotherapy of cancer
|
US8114414B2
(en)
*
|
1994-11-08 |
2012-02-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of cervical cancer
|
US7820180B2
(en)
*
|
2004-09-24 |
2010-10-26 |
The Trustees Of The University Of Pennsylvania |
Listeria-based and LLO-based vaccines
|
US5843648A
(en)
*
|
1995-01-10 |
1998-12-01 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
|
EP0914607A2
(de)
*
|
1995-09-15 |
1999-05-12 |
Samir Chachoua |
Verfahren zur erkennung und therapeutische verwendung von krankheitsassoziierten organismen, elementen und kräften
|
US7501501B2
(en)
*
|
1995-09-26 |
2009-03-10 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
MHC-Class II restricted melanoma antigens and their use in therapeutic methods
|
US6951917B1
(en)
|
1995-09-26 |
2005-10-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
MHC-class II restricted melanoma antigens and their use in therapeutic methods
|
US20040156861A1
(en)
*
|
1996-07-11 |
2004-08-12 |
Figdor Carl Gustav |
Melanoma associated peptide analogues and vaccines against melanoma
|
EP0959893A4
(de)
*
|
1996-12-10 |
2004-11-10 |
Sloan Kettering Institutefor C |
Stimulierung einer immunantwort auf ein differentiationsantigen, das durch ein verändertes antigen stimuliert wird
|
US7556805B2
(en)
*
|
1996-12-10 |
2009-07-07 |
Sloan-Kettering Inststute for Cancer Research and The Animal Medical Center |
Compositions for treatment of melanoma and method of using same
|
US20100068216A1
(en)
*
|
1997-02-18 |
2010-03-18 |
Sloan-Kettering Institute For Cancer Research |
Method and Compositions for Stimulation of an Immune Response to gp100 using a Xenogeneic gp100 Antigen
|
US20020155093A1
(en)
*
|
1997-02-18 |
2002-10-24 |
Houghton Alan N. |
Method for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
|
US20100068262A1
(en)
*
|
1997-02-18 |
2010-03-18 |
Sloan-Kettering Institute For Cancer Research |
Method and Compositions for Stimulation of an Immune Response to PSMA using a Xenogeneic PSMA Antigen
|
US8021666B2
(en)
*
|
1997-02-18 |
2011-09-20 |
Sloan-Kettering Institute For Cancer Research |
Method and compositions for stimulation of an immune response to CD20 using a xenogeneic CD20 antigen
|
US20100068263A1
(en)
*
|
1997-02-18 |
2010-03-18 |
Sloan-Kettering Institute For Cancer Research |
Method and Compositions for Stimulation of an Immune Response to TRP2 using a Xenogeneic TRP2 Antigen
|
DE19821925A1
(de)
*
|
1998-05-15 |
1999-11-18 |
Roehnisch Tim |
Verfahren zur Herstellung einer Zusammensetzung zur Induktion einer tumorspezifischen Immunantwort, sowie Verwendung der Zusammensetzung zur Behandlung von Neoplasien
|
AU4188100A
(en)
|
1999-04-08 |
2000-11-14 |
Gregory M. Glenn |
Dry formulation for transcutaneous immunization
|
AU2001234616A1
(en)
*
|
2000-01-31 |
2001-08-07 |
Vic Jira |
Vaccine composition, process and methods
|
JP2003525038A
(ja)
*
|
2000-02-08 |
2003-08-26 |
ユニバーシティー オブ ブリティッシュ コロンビア |
治療薬をスクリーニングするための組成物および方法
|
US9012141B2
(en)
|
2000-03-27 |
2015-04-21 |
Advaxis, Inc. |
Compositions and methods comprising KLK3 of FOLH1 antigen
|
AU2001255196A1
(en)
*
|
2000-03-29 |
2001-10-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for enhancing immunogenicity of antigens
|
US6855320B2
(en)
*
|
2000-03-29 |
2005-02-15 |
The Trustees Of The University Of Pennsylvania |
Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
|
US7700344B2
(en)
*
|
2001-03-26 |
2010-04-20 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for enhancing the immunogenicity of antigens
|
US8771702B2
(en)
*
|
2001-03-26 |
2014-07-08 |
The Trustees Of The University Of Pennsylvania |
Non-hemolytic LLO fusion proteins and methods of utilizing same
|
US7419957B2
(en)
*
|
2001-08-22 |
2008-09-02 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods
|
CA2457520A1
(en)
*
|
2001-08-30 |
2003-03-13 |
Biorexis Pharmaceutical Corporation |
Modified transferrin fusion proteins
|
US20030226155A1
(en)
*
|
2001-08-30 |
2003-12-04 |
Biorexis Pharmaceutical Corporation |
Modified transferrin-antibody fusion proteins
|
US8129504B2
(en)
|
2001-08-30 |
2012-03-06 |
Biorexis Technology, Inc. |
Oral delivery of modified transferrin fusion proteins
|
US7176278B2
(en)
*
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
US20070031440A1
(en)
*
|
2001-08-30 |
2007-02-08 |
Prior Christopher P |
Modified transferin-antibody fusion proteins
|
CN102268094A
(zh)
*
|
2002-08-30 |
2011-12-07 |
比奥雷克西斯药物公司 |
被修饰的转铁蛋白抗体的融合蛋白
|
US20060105387A1
(en)
*
|
2002-08-30 |
2006-05-18 |
Prior Christopher P |
Transferrin fusion proteins libraries
|
US20070060512A1
(en)
*
|
2003-03-04 |
2007-03-15 |
Homayoun Sadeghi |
Dipeptidyl-peptidase protected protein
|
US7379700B2
(en)
*
|
2003-05-06 |
2008-05-27 |
Canon Kabushiki Kaisha |
Image reading apparatus with rotatable internal and external guides
|
US8207314B2
(en)
*
|
2003-05-16 |
2012-06-26 |
Sanofi Pasteur Limited |
Tumor antigens for prevention and/or treatment of cancer
|
US20060205037A1
(en)
*
|
2003-08-28 |
2006-09-14 |
Homayoun Sadeghi |
Modified transferrin fusion proteins
|
EP1663278A4
(de)
*
|
2003-08-28 |
2009-07-29 |
Biorexis Pharmaceutical Corp |
Epo mimetika-peptide und fusionsproteine
|
EP1928537B1
(de)
|
2005-09-02 |
2015-01-21 |
Intercell USA, Inc. |
Vorrichtungen für die transkutane Abgabe von Vakzine und transdermale Abgabe von Arzneimittel
|
CN101511868B
(zh)
|
2006-07-24 |
2013-03-06 |
比奥雷克西斯制药公司 |
毒蜥外泌肽融合蛋白
|
WO2008019131A2
(en)
*
|
2006-08-04 |
2008-02-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating ige-mediated diseases
|
US8268326B2
(en)
*
|
2006-08-15 |
2012-09-18 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
|
US8241636B2
(en)
*
|
2006-08-15 |
2012-08-14 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
|
US20110129499A1
(en)
|
2008-05-19 |
2011-06-02 |
Paulo Maciag |
Dual delivery system for heterologous antigens
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
US20090005320A1
(en)
*
|
2008-09-02 |
2009-01-01 |
Bruce Kneller |
Compositions comprising amino acid bicarbonate and methods of use thereof
|
ES2637068T3
(es)
|
2009-03-04 |
2017-10-10 |
The Trustees Of The University Of Pennsylvania |
Composiciones que comprenden factores angiogénicos y métodos de uso de las mismas
|
CN102573883A
(zh)
|
2009-06-12 |
2012-07-11 |
疫苗技术公司 |
用于促进细胞-介导的免疫应答的方法和组合物
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
US9226958B2
(en)
|
2010-10-01 |
2016-01-05 |
University Of Georgia Research Foundation, Inc. |
Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
EP2683400A4
(de)
|
2011-03-11 |
2014-09-17 |
Advaxis |
Adjuvanzien auf listerien-basis
|
SG11201405605VA
(en)
|
2012-03-12 |
2014-10-30 |
Advaxis Inc |
SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
|
WO2014044690A1
(en)
|
2012-09-18 |
2014-03-27 |
Valneva Austria Gmbh |
Improved vaccines
|